Castle Biosciences to Present at Three Investor Conferences in September 2025

Castle Biosciences will participate in three investor conferences in September 2025, including a presentation at Baird's Global Healthcare Conference on September 10. The company's management team will also be available for one-on-one meetings at the Wells Fargo and Lake Street Best Ideas Growth Conferences. Investors can coordinate meetings through the respective firms. Castle Biosciences is focused on developing diagnostic tests for skin cancers, Barrett's esophagus, and uveal melanoma, among other conditions.

Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, has announced its participation in three upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10 at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website. Additionally, Castle's management will be available for one-on-one meetings during the Wells Fargo Healthcare Conference on September 4 and the Lake Street Best Ideas Growth Conference on September 11. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets.

Castle Biosciences aims to improve health through innovative tests that guide patient care. The company's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma. Additionally, Castle Biosciences has active research and development programs for tests in these and other diseases with high clinical need, including a test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment.

Investors can coordinate meetings with Castle Biosciences' management through Wells Fargo and Lake Street Capital Markets. For more information, please visit www.CastleBiosciences.com and connect with them on LinkedIn, Facebook, X, and Instagram.

References:
[1] https://www.stocktitan.net/news/CSTL/castle-biosciences-to-participate-in-upcoming-investor-g51lxflqidnb.html